Search Result

Results for "

ovarian cancer xenograft mouse models

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) Adrenergic Receptor (1) Akt (1) Antibody-Drug Conjugates (ADCs) (1) Antifolate (1) Apelin Receptor (APJ) (1) Apoptosis (5) Bcl-2 Family (1) Beta-secretase (1) CD3 (1) CDK (1) Drug-Linker Conjugates for ADC (1) ERK (1) GABA Receptor (1) GnRH Receptor (1) HSP (1) Lipase (1) MDM-2/p53 (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Mps1 (1) mTOR (2) Phosphatase (1) PI3K (1) Ras (1) Reactive Oxygen Species (ROS) (1) SHMT (1) Topoisomerase (1) Transmembrane Glycoprotein (1) Wee1 (1)
By Research Areas:	Cancer (17) Endocrinology (1)

By Targets:

ADC Antibody (1)

Adrenergic Receptor (1)

Akt (1)

Antibody-Drug Conjugates (ADCs) (1)

Antifolate (1)

Apelin Receptor (APJ) (1)

Apoptosis (5)

Bcl-2 Family (1)

Beta-secretase (1)

CD3 (1)

CDK (1)

Drug-Linker Conjugates for ADC (1)

ERK (1)

GABA Receptor (1)

GnRH Receptor (1)

HSP (1)

Lipase (1)

MDM-2/p53 (1)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (1)

Mps1 (1)

mTOR (2)

Phosphatase (1)

PI3K (1)

Ras (1)

Reactive Oxygen Species (ROS) (1)

SHMT (1)

Topoisomerase (1)

Transmembrane Glycoprotein (1)

Wee1 (1)

By Research Areas:

Cancer (17)

Endocrinology (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: BCRP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-164734

Raludotatug Deruxtecan R-DXd; DS-6000	Antibody-Drug Conjugates (ADCs)	Cancer
Raludotatug Deruxtecan is an antibody-drug conjugate targeting CDH6, with an EC₅₀ of 64.7 ng/mL in humans, 70.4 ng/mL in cynomolgus monkeys, and 228 ng/mL in mice. Raludotatug Deruxtecan specifically binds to CDH6 on the surface of cancer cells, triggers lysosomal internalization, and releases the DXd payload that inhibits TOP1. Raludotatug Deruxtecan induces DNA damage, Chk1 phosphorylation, caspase-3 cleavage, apoptosis, and bystander cell death. Raludotatug Deruxtecan is applicable to research related to serous ovarian cancer and renal cell carcinoma .

HY-139852

PLAP-IN-1	Phosphatase	Cancer
PLAP-IN-1 is a selective PLAP inhibitor with an IC₅₀ of 0.032 μM. PLAP-IN-1 acts as a tumor-targeting agent; its fluorescein-conjugated derivative specifically binds to PLAP-positive tumor cells in vitro and targets cervical cancer in mouse xenograft models. PLAP-IN-1 can be used in the research of cervical cancer and ovarian cancer .

HY-P990953

Zubotamig Gen1047	CD3	Cancer
Zubotamig (Gen1047) is an CD3E/VTCN1-targeting Ig(G1 -κ_G1 -λ2) type chimeric human antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zubotamig induces T-cell mediated cytotoxicity of B7H4-positive tumor cells, triggers T-cell activation, and induces cytokine release from T cells in the presence of B7H4-expressing tumor cells. Zubotamig demonstrates antitumor activity in mouse patient-derived xenograft (PDX) models. Zubotamig can be used for the research of solid cancers (including breast, ovarian and lung cancer) .

HY-P4144

Onvitrelin ucalontide Phor18-LHRH (338613); EP-100	GnRH Receptor	Endocrinology Cancer
Onvitrelin ucalontide ([Phor18-LHRH (338613)]) is an analogue of luteinizing hormone releasing hormone (LHRH) with antineoplastic activity. Onvitrelin ucalontide is a peptide with sequences of KFAKFAKKFAKFAKKFAKQHWSYGLRPG. Onvitrelin ucalontide effectively inhibits breast cancer, ovarian cancer and prostate cancer xenografts in mouse model .

HY-186151

UCI-LC0019	MDM-2/p53 Apoptosis	Cancer
UCI-LC0019 is a mutant p53 reactivator. UCI-LC0019 binds to mutant p53, induces wild-type-like conformational change, restores sequence-specific DNA binding activity, activates p53-dependent transcription programs, and does not act via thiol reactivity or glutathione depletion. UCI-LC0019 inhibits proliferation and induces apoptosis in cancer cells harboring mutant p53, with no significant effect on p53 ^null or wild-type p53 tumors cells. UCI-LC0019 exhibits anti-tumor activity in xenograft mouse models carrying p53^R175H mutant tumors. UCI-LC0019 can be used for the research of cancer, such as ovarian cancer .

HY-P992441

PHST001	Transmembrane Glycoprotein	Cancer
PHST001 is a humanized anti-CD24 antibody. PHST001 binds cell-surface CD24, blocks CD24-Siglec10 interaction, and engages Fc receptors to promote macrophage-mediated tumor cell phagocytosis. PHST001 inhibits growth of breast cancer and ovarian cancer, and reduces metastatic lesions in mouse xenograft models. PHST001 can be used for the research of triple negative breast cancer, HER2+ breast cancer, metastatic tumors, and ovarian cancer .

HY-176957

PKMYT1-IN-11	Wee1	Cancer
PKMYT1-IN-11 (Example 1) is a PKMYT1 inhibitor with an IC₅₀ of 4.49 nM. PKMYT1-IN-11 inhibits the proliferation of HCC1569 cells. When combined with Gemcitabine (HY-17026), PKMYT1-IN-11 shows a significant anti-tumor effect in the OVCAR3 xenograft mouse model. PKMYT1-IN-11 can be used for the study of various cancers such as breast cancer and ovarian cancer .

HY-177092

AGF347	Antifolate SHMT Apoptosis mTOR Reactive Oxygen Species (ROS) Mitochondrial Metabolism	Cancer
AGF347 is a potent and multi-targeted antifolate that targets serine hydroxymethyltransferase (SHMT)2 in the mitochondria and SHMT1 in the cytosol, and inhibits de novo purine biosynthesis. AGF347 induces apoptosis, inhibits mTOR signaling, decreases GSH pools, and increases ROS. AGF347 inhibits proliferation of Cisplatin (HY-17394) sensitive and resistant epithelial ovarian cancer (EOC) cells. AGF347 exhibits antitumor efficacy in SKOV3 EOC xenograft mouse models. AGF347 can be used for ovarian cancer research .

HY-P992003

IKS012 Antibody IKS01 Antibody	ADC Antibody	Cancer
IKS012 (IKS01) Antibody is a monoclonal antibody inhibitor targeting folate receptor α (FRA). IKS012 Antibody can be used to synthesize the antibody-drug conjugate (ADC) IKS012. IKS012 Antibody can be used to research related to platinum-resistant ovarian cancer .

HY-184010

KRASG12D-IN-8	Ras ERK	Cancer
KRASG12D-IN-8 is an orally active KRAS ^G12D inhibitor, with a K_d value of 0.003 nM for KRAS ^G12D and 0.024 nM for KRAS ^G12V. KRASG12D-IN-8 inhibits the activity of phosphorylated ERK in KRAS-mutated cells. KRASG12D-IN-8 induces tumor regression in ovarian cancer xenograft mouse models. KRASG12D-IN-8 can be used for the research of KRAS-mutated cancers .

HY-179430

TTK-IN-5	Mps1	Cancer
TTK-IN-5 is an orally active covalent threonine tyrosine kinase (TTK) inhibitor with selectivity (IC₅₀ = 8.918 nM). TTK-IN-5 exhibits anti-proliferative potencies against MDA-MB-231, A2780, HCT116, HCC1569 and MKN1 cell lines (IC₅₀ values of 0.113 μM, 0.476 μM, 3.136 μM, 3.649 μM, and 1.856 μM, respectively). TTK-IN-5 potently suppresses tumor growth without notable toxicity in A2780 and MDA-MB-231 xenograft mouse models. TTK-IN-5 can be used for the research of cancer such as breast cancer and ovarian cancer .

HY-183329

Tubulin polymerization-IN-92	Microtubule/Tubulin Apoptosis	Cancer
Tubulin polymerization-IN-92, an analog of KX-01 (HY-10340), is a potent orally active tubulin polymerization inhibitor that binds tubulin with a K_a of 1.29 μM. Tubulin polymerization-IN-92 simultaneously occupies the colchicine site in β-tubulin and a cavity in α-tubulin. Tubulin polymerization-IN-92 exerts antiproliferative activity, induces G2/M cell cycle arrest and apoptosis in cancer cells. Tubulin polymerization-IN-92 inhibits tumor growth in mouse xenograft models. Tubulin polymerization-IN-92 can be used for the research of colon cancer, cervical cancer, and Paclitaxel (HY-B0015)-resistant ovarian cancer .

HY-N1255A

Scoulerine hydrochloride (-)-Scoulerine hydrochloride; Discretamine hydrochloride	Apoptosis PI3K Akt mTOR Adrenergic Receptor GABA Receptor Beta-secretase Bcl-2 Family	Cancer
Scoulerine ((-)-Scoulerine; Discretamine) hydrochloride is a multi-target inhibitor with anti-tumor and antioxidant activities. Scoulerine hydrochloride mainly targets the PI3K/Akt/mTOR signaling axis and α1D-adrenergic receptor, disrupts microtubule structure, and induces cell cycle arrest and apoptosis. Scoulerine hydrochloride effectively inhibits mitochondrial dehydrogenase activity, targets GABA receptors and BACE1, and suppresses the proliferation, migration, invasion, epithelial-mesenchymal transition and stem cell properties of cancer cells. Scoulerine hydrochloride also exhibits multiple pharmacological activities including anti-Plasmodium falciparum, antibacterial, antiemetic and antitussive effects, and regulates endoplasmic reticulum stress and mitochondrial function (modulates Bax, Bcl-2 and cytochrome c). Scoulerine hydrochloride is applicable to research related to leukemia, ovarian cancer, and colorectal cancer .

HY-181687

Hsp90-IN-46	HSP CDK	Cancer
Hsp90-IN-46 is a Hsp90 inhibitor. Hsp90-IN-46 exhibits broad-spectrum antiproliferative activity against tumor cell lines. Hsp90-IN-46 inhibits breast cancer cell proliferation by reducing colony formation and downregulating the proliferation marker Ki-67. Hsp90-IN-46 inhibits Hsp90 and its ATPase activity, downregulates the downstream substrate oncoproteins HER2 and CDK4, and moderately induces the heat shock response. Hsp90-IN-46 shows significant antitumor activity in a mouse model of triple-negative breast cancer tumor xenografts. Hsp90-IN-46 can be used for research on various cancers including triple-negative breast cancer, leukemia, non-small cell lung cancer, colon cancer, ovarian cancer, renal cancer, prostate cancer .

HY-181540

YL-GB063	Apelin Receptor (APJ)	Cancer
YL-GB063 is an Apelin receptor (APJ) antagonist. YL-GB063 inhibits Apelin-induced APJ β-arrestin recruitment (IC₅₀ of 3.1 μM in HTLA cells). YL-GB063 has anti-cancer activity against ovarian cancer .

HY-183558

AV-DL055	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
AV-DL055 is a conjugate of the toxin molecule Exatecan (HY-13631) and the linker AV-L03 (HY-183678). AV-DL055 can be used to construct ADCs, such as T-DL055 .

HY-181986

ERX-208	Lipase Apoptosis	Cancer
ERX-208 is an anticancer agent that induces endoplasmic reticulum stress by targeting lysosomal acid lipase A (LIPA), ultimately leading to cancer cell apoptosis. ERX-208 can be used in ovarian cancer research .

Cat. No.	Product Name	Target	Research Area